Expression and cytoplasmic localization of SAM68 is a significant and independent prognostic marker for renal cell carcinoma

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 10, 2009, Pages 2685-2693

  Zhang, Zhiling ^a,b   Li, Jun ^c   Zheng, Haiqing ^b   Yu, Chunping ^a,b   Chen, Jin ^d   Liu, Zhuowei ^b   Li, Manzhi ^a,b   Zeng, Musheng ^a,b   Zhou, Fangjian ^a,b   Song, Li Bing ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d Guangzhou Science City   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PROTEIN SAM68;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY TUBULE EPITHELIUM; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BLOTTING, WESTERN; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CYTOPLASM; DISEASE PROGRESSION; DNA-BINDING PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MULTIVARIATE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA-BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 70350094406     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-09-0097     Document Type: Article

References (46)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics: 1999. CA Cancer J Clin 1999;49:8-31.
2. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001;166:1611-1623 (Pubitemid 34225128)
3. Chow WH, Devesa SS, Warren JL, Fraumeni JF, Jr. Rising incidence of renal cell cancer in the United States. JAMA 1999;281:1628-1631
4. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
5. Belldegrun AS, Klatte T, Shuch B, et al. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies. Cancer 2008;113:2457-2463
6. Fumagalli S, Totty NF, Hsuan JJ, Courtneidge SA. A target for Src in mitosis. Nature 1994;368:871-874
7. Taylor SJ, Shalloway D. An RNA-binding protein associated with Src through its SH2 and SH3 domains in mitosis. Nature 1994;368:867-871 (Pubitemid 24137753)
8. Vernet C, Artzt K. STAR, a gene family involved in signal transduction and activation of RNA. Trends Genet 1997;13:479-484 (Pubitemid 28004921)
9. Chen T, Damaj BB, Herrera C, Lasko P, Richard S. Self-association of the single-KH-domain family members SAM68, GRP33, GLD-1, and Qk1: role of the KH domain. Mol Cell Biol 1997;17:5707-5718. (Pubitemid 27411078)
10. Lin Q, Taylor SJ, Shalloway D. Specificity and determinants of SAM68 RNA binding. Implications for the biological function of K homology domains. J Biol Chem 1997;272:27274-27280 (Pubitemid 27452690)
11. Wang LL, Richard S, Shaw AS. p62 association with RNA is regulated by tyrosine phosphorylation. J Biol Chem 1995;270:2010-2013
12. Derry JJ, Richard S, Valderrama Carvajal H, et al. Sik (BRK) phosphorylates SAM68 in the nucleus and negatively regulates its RNA binding ability. Mol Cell Biol 2000;20:6114-6126 (Pubitemid 30613059)
13. Babic I, Jakymiw A, Fujita DJ. The RNA binding protein SAM68 is acetylated in tumor cell lines, and its acetylation correlates with enhanced RNA binding activity. Oncogene 2004;23:3781-3789 (Pubitemid 38725691)
14. Côté J, Boisvert FM, Boulanger MC, Bedford MT, Richard S. SAM68 RNA binding protein is an in vivo substrate for protein arginine N-methyltransferase 1. Mol Biol Cell 2003;14:274-287 (Pubitemid 36106036)
15. Liu K, Li L, Nisson PE, Gruber C, Jessee J, Cohen SN. Neoplastic transformation and tumorigenesis associated with SAM68 protein deficiency in cultured murine fibroblasts. J Biol Chem 2000;275:40195-40201 (Pubitemid 32064649)
16. Taylor SJ, Resnick RJ, Shalloway D. SAM68 exerts separable effects on cell cycle progression and apoptosis. BMC Cell Biol 2004;5:5-11. (Pubitemid 38597779)
17. Li QH, Haga I, Shimizu T. Retardation of the G2-M phase progression on gene disruption of RNA binding protein SAM68 in the DT40 cell line. FEBS Lett 2002;525:145-150 (Pubitemid 34886391)
18. Barlat I, Maurier F, Duchesne M, Guitard E, Tocque B, Schweighoffer FA. Role for SAM68 in cell cycle progression antagonized by a spliced variant within the KH domain. J Biol Chem 1997;272:3129-3132 (Pubitemid 27066796)
19. Trifillis AL, Regec AL, Trump BF. Isolation, culture and characterization of human renal tubular cells. J Urol 1985;133:324-329 (Pubitemid 15158441)
20. Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual, 6th ed. New York: Springer-Verlag; 2002. p. 323-325
21. Ebele JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and genetics of tumors of the urinary system and male genital organs, 3th ed. Lyon: IARC; 2004. p. 12-43.
22. Fuhrman SA, Lasky LC, Limas C. Prognostic significance ofmorphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982;6:655-663 (Pubitemid 13234762)
23. Collett K, Eide GE, Arnes J, et al. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res 2006;12:1168-1174 (Pubitemid 43342505)
24. Salvesen HB, MacDonald N, Ryan A, et al. Methylation of hMLH1 in a population-based series of endometrial carcinomas. Clin Cancer Res 2000;6:3607-3613 (Pubitemid 30694944)
25. Yu C, Chen K, Zheng H, et al. Overexpression of astrocyte elevated gene-1 (AEG-1) is associated with esophageal squamous cell carcinoma (ESCC) progression and pathogenesis. Carcinogenesis 2009;30: 894-901.
26. Saussez S, Cucu DR, Decaestecker C, et al. Galectin 7 (p53-induced gene 1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer. Ann Surg Oncol 2006;13:999-1009. (Pubitemid 43920934)
27. Singh SS, Li Y, Ford OH, et al. Thioredoxin reductase 1 expression and castration-recurrent growth of prostate cancer. Transl Oncol 2008;1: 153-157
28. Bao S, Ouyang G, Bai X, et al. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 2004;5:329-339 (Pubitemid 38482069)
29. Lam JS, Klatte T, Kim HL, et al. Prognostic factors and selection for clinical studies of patients with kidney cancer. Crit Rev Oncol Hematol 2008;65:235-262 (Pubitemid 351174051)
30. Nogueira M, Kim HL. Molecular markers for predicting prognosis of renal cell carcinoma. Urol Oncol 2008;26:113-124 (Pubitemid 351288566)
31. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003; 9:802-811 (Pubitemid 36182618)
32. Gilbert SM, Whitson JM, Mansukhani M, et al. Detection of carbonic anhydrase-9 gene expression in peripheral blood cells predicts risk of disease recurrence in patients with renal cortical tumours. Urology 2006;67:942-945 (Pubitemid 43956430)
33. Zigeuner R, Ratschek M, Rehak P, Schips L, Langner C. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue. Urology 2004;63:651-655 (Pubitemid 38479402)
34. Kim HL, Seligson D, Liu X, et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 2004;10: 5464-5471 (Pubitemid 39100484)
35. Kim HL, Seligson D, Liu X, et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 2005; 173:1496-1501 (Pubitemid 40524757)
36. Klatte T, Seligson DB, Leppert JT, et al. The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma. J Urol 2008;179:61-66 (Pubitemid 350216740)
37. Busà R, Paronetto MP, Farini D, et al. The RNA-binding protein SAM68 contributes to proliferation and survival of human prostate cancer cells. Oncogene 2007;26:4372-4382 (Pubitemid 47014462)
38. Lazer G, Pe'er L, Schapira V, Richard S, Katzav S. The association of SAM68 with Vav1 contributes to tumorigenesis. Cell Signal 2007;19: 2479-2486
39. Richard S, Vogel G, Huot ME, Guo T, Muller WJ, Lukong KE. SAM68 haploinsufficiency delays onset of mammary tumorigenesis and metastasis. Oncogene 2008;27:548-556
40. Chen T, Boisvert FM, Bazett-Jones DP, Richard S. A role for the GSG domain in localizing SAM68 to novel nuclear structures in cancer cell lines. Mol Biol Cell 1999;10:3015-3033 (Pubitemid 29441579)
41. Paronetto MP, Achsel T, Massiello A, Chalfant CE, Sette C. The RNA-binding protein SAM68 modulates the alternative splicing of Bcl-xL. J Cell Biol 2007;176:929-939 (Pubitemid 46506967)
42. Lukong KE, Larocque D, Tyner AL, Richard S. Tyrosine phosphorylation of sam68 by breast tumor kinase regulates intranuclear localization and cell cycle progression. J Biol Chem 2005;280:38639-38647 (Pubitemid 43853766)
43. + T cells is dependent on CD4 molecule expression. J Immunol 1998;161:2798-2803
44. Martín-Romero C, Sánchez-Margalet V. Human leptin activates PI3K and MAPK pathways in human peripheral blood mononuclear cells: possible role of SAM68. Cell Immunol 2001;212:83-91. (Pubitemid 34044539)
45. Sánchez-Margalet V, Najib S. SAM68 is a docking protein linking GAP and PI3K in insulin receptor signaling. Mol Cell Endocrinol 2001;183: 113-121 (Pubitemid 32938517)
46. Gorla L, Cantù M, Miccichè F, et al. RET oncoproteins induce tyrosine phosphorylation changes of proteins involved in RNA metabolism. Cell Signal 2006;18:2272-2282 (Pubitemid 44636167)